Hi seanl, IMO, drip-feeding of efficacy data could seriously...

Hi seanl, IMO, drip-feeding of efficacy data could seriously prevent patient enrolment. Imagine if the two participants in cohort 3 showed early clearance, then relapsed, and this was reported. It would be very difficult to find a third participant because they would likely only want to be involved at a higher dose, preventing the trial from continuing at all. Benitec have been under fire for reporting on a case-by-case basis in the past and reporting early creates an unrealisted expection, seriously damaging the share price when 'expected' dosing is not reported.